
Lemborexant (CAS: 1369764-02-2), developed by Eisai Co., Ltd. of Japan, is the world's first dual orexin receptor antagonist (DORA). It is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults, first launched in the US on December 20, 2019. It regulates sleep by blocking OX1R and OX2R to achieve natural sleep effects with high safety profile.
×